S
UBARACHNOID hemorrhage (SAH) from rupture of intracranial arterial aneurysms may be followed by cerebral vasospasm. ~6 The concomitant cerebral ischemia ~5 and neurological deficits are associated with increased morbidity and mortality. ~6 The capricious nature of pathological cerebral arterial spasm has made investigation of this phenomenon difficult, and its etiology remains obscure. However, in 1964, Buckel114 demonstrated the presence of vasoconstrictor material in cerebrospinal fluid (CSF) and hematoma fluid from SAH patients, implying that the syndrome had a pharmacological basis. Subsequently, Blaso and Boullin 5 reported a study of the vasoconstrictor activity in CSF collected from patients after aneurysm surgery. Increasing CSF vasoactivity was associated with angiographic cerebral vasospasm leading to morbidity and mortality. Attempts to extend these observations to the period when pathological vasospasm has most often been reported (4 to 17 days post-SAH), 24' 2~ by sampling CSF before conventionally timed surgery ~j' 2~ and after early surgery, 83j failed to reveal any close relationship between vasoconstrictor activity and morbidity.
We are reporting a study of 32 patients with SAH,
showing that high levels of smooth-muscle constrictor activity in the CSF are associated (although not invariably) with severe angiographic vasospasm, delayed ischemic deficits, and subsequent mortality.
Clinical Material and Methods

Collection of CSF
Cerebrospinal fluid was collected by lumbar puncture after the patients' admission, and at operation 44 by lumbar or ventricular drain, from 32 patients with SAH, We also obtained CSF from six control patients (Table  1) without evidence of subarachnoid blood. Overtly red-colored CSF was centrifuged for 5 minutes at 6500 G to remove whole cells and particulate matter. The CSF was then frozen to -20~ until required for bioassay. In a single patient (Case 2, Table 2 ), serial CSF samples were obtained by repeated lumbar puncture, In three patients (Cases 3, 6, and 17, Table 2 ), both lumbar and ventricular CSF samples were collected.
Bioassay for Vasoconstrictor Activity
Male Sprague-Dawley rats were stunned, then sacri- continuously aerated with a mixture of 5% CO2 and 95% 02. Isotonic contractions were recorded on a potentiometric chart-recorder/~ In a single experiment, an isolated human basilar artery ~~ replaced the rat stomach strip.
After an initial equilibration period, preparations were repeatedly challenged with prostaglandin E2 (PGE2: bath concentration 2 x 10 -8 M) or 5-hydroxytryptamine (5-HT, serotonin) until reproducible responses were observed. Partial dose-response curves to PGE2 or 5-HT (bath concentrations 10 -9 to 2 x 10 -7 Concentrations of smooth-muscle constrictor material (SMC Activity) were estimated on the isolated rat fundus. Values for SMC activity in CSF are given in PGE2 equivalents (nmol/liter) for 500 ul added to a 5-ml bath. Spasm denotes the degree of arterial narrowing seen at angiography (see the Methods section for definitions). The clinical condition of patients was estimated on the scale described by Hunt and Hessfl 2 Grading was performed after admission, at surgery (if performed), and, in some cases, where there was maximal improvement or deterioration in the intervening period (Mid-Term). Outcome is defined in the Methods section. M) were obtained, and the preparations challenged with 500 ul of control CSF or CSF collected from patients with SAH. All contractile responses to CSF fell within the above range, and were measured as the equivalent bath concentration of PGE2 or 5-HT (PGEj5-HT equivalents, nmol/liter) required to elicit a contraction of the same magnitude. These values were derived from the dose-response curves for PGE2 or 5-HT obtained for each preparation. 8 For statistical analysis, all values were expressed in terms of PGE2 equivalents (nmol/ liter) using a dose ratio of 4.2:1 (bath concentration PGE2/5-HT) derived from preliminary experiments.
A ngiography
Angiographic cerebral vasospasm was assessed as described by Adams, et al. 1 Angiograms were measured at the positions described, and the sum of the values obtained (after correction for magnification) was compared with the normal diameters given by Gabrielsen and Greitz. 18 The middle cerebral artery (normal diameter 3.82 _+ 0.43 mm) and anterior cerebral artery (normal diameter 3.02 _+ 0.43 ram) were measured at a point 5 mm beyond their origins. The internal carotid artery (ICA) was measured at a point 5 mm proximal to its termination (normal diameter 4.57 + 0.46 ram). Severe vasospasm was defined as a mean arterial narrowing of greater than 50%, in combination with a segmental reduction in diameter to less than 2 mm in the ICA or 1 mm in the A~ or M~ segments. Moderate vasospasm was said to be present when there was a mean arterial narrowing of greater than 50% without the segmental narrowing seen in severe vasospasm. Mild vasospasm was regarded as a mean arterial narrowing of 20% to 50%. Less than 20% narrowing was not regarded as vasospasm.
Clinical Evaluation
The clinical condition of the patients was rated according to the scale of Hunt and Hess. 22 Patients were graded on admission, at the time of CSF sampling, and at the time of surgery. Patients underwent additional grading at times of maximal clinical improvement or deterioration following admission.
Outcome
Outcome of patients admitted with SAH was assessed 3 months after admission. 2 Patients able to return to their former life-style and occupation were regarded as having a good outcome. A fair result meant that the patient could not resume his original occupation due to residual neurological deficits, although all these patients were able to return to a modified or part-time occupation. The outcome in patients who were unable to work at 3 months after admission and needed assistance was described as "poor." For purposes of data analysis, a good outcome was ranked 1, fair was 2, and poor was ranked 3. Patients who died were ranked 4. Data were analyzed by linear regression and an unpaired two-tailed t-test.
Results
Samples of Cerebrospinal Fhdd
The CSF was sampled from six control patients (Table 1) and 32 patients admitted with SAH after aneurysm rupture ( Table 2 ). The CSF was collected between 3 and 42 days after SAH, with a mean time and standard error of collection at 11.1 + 1.5 days. In a single patient (Case 2), four samples of CSF were obtained at intervals of between 7 and 14 days after SAH. The values for the last collected samples only are presented in Table  2 . In three patients (Cases 3, 6, and 17), both lumbar and ventricular CSF samples were obtained. Times of sampling for these patients are given in Table 3 .
Angiographic and Clinical Assessment of Vasospasm
Cerebral angiography was performed in 26 patients between 6 and 29 days after the initial hemorrhage (mean 10.9 + 1.1 days). Severe angiographic vasospasm was detected in seven (27%) patients (Cases 1, 2, 3, 11, 14, 15, and 16). In four patients (Cases 1, 2, 3, and 11), this severe angiographic vasospasm was accompanied by delayed ischemic deficits, resulting in death in Cases 1, 2, and 3. A single patient (Case 10) had angiographic spasm of moderate severity, with associated cerebral ischemia and a subsequent poor outcome.
Mild cerebral vasospasm was demonstrated at angiography in four patients (Cases 17 to 20), with accompanying neurological deficits in one (Case 17). Six patients (Cases 4 to 9) had severe neurological deficits (Grade IV) at the time of CSF sampling, but angiography was not performed due to their poor condition.
Outcome
Of 32 patients with SAH, seven (21.9%) died before surgery could be performed, between 6 and 18 days after SAH (mean 10.4 + 2.1 days, Table 2 ). All these patients showed signs of delayed ischemic deficits, with angiographic confirmation of vasospasm in three (Cases 1, 2, and 3).
Three patients (9.5%) had a poor outcome. They were in Hunt and Hess Grade III and IV on admission (Cases 8, 9, and 10). Only one of these (Case 10) had angiography, and subsequent aneurysm surgery 30 days after SAH.
A fair outcome was seen in three patients (9.5%) all of whom underwent aneurysm surgery. Of these patients, Case 11 showed severe angiographic vasospasm with concomitant neurological deficits 7 days after SAH, but recovered sufficiently for successful aneurysm surgery to be performed on Day 38.
A good outcome resulted in 19 patients (59%), all of whom underwent aneurysm surgery. In this group, a single patient (Case 17) developed delayed neurological deficits on Day 12. However, these had resolved sufficiently by Day 29 to allow angiography (which demonstrated mild vasospasm), and surgery on Day 30, following which there was a good recovery.
Smooth-Muscle Constrictor Activity in C S F
Lumbar Versus Ventricular CSF. Of 36 samples of CSF collected from 32 SAH patients (Table 2) , 30 were obtained from the lumbar subarachnoid space, and six from the ventricles. The mean smooth-muscle constrictor activity in lumbar CSF samples was 20.1 _ 10.1 nmol/liter PGE2 equivalents. This was slightly, but not significantly (unpaired t-test), higher than the mean value detected in the ventricular CSF (14.6 _ 11.9 nmol/liter PGE2 equivalents). Too few samples were collected from the ventricles to allow meaningful comparisons of CSF smooth-muscle constrictor activity within outcome groups. However, lumbar and ventricular CSF samples were obtained from three patients (Cases 3, 6, and 17). For the values in those patients see Table 3 . The only major difference is seen with Case 3, where a high value for smooth-muscle constrictor activity in ventricular CSF, sampled 7 days after lumbar CSF was obtained, coincided with the onset of delayed ischemic deficits.
Correlation with Angiographic Vasospasm. The mean smooth-muscle constrictor activity detected in lumbar and ventricular CSF from 32 SAH patients was 21.2 _+ 9.6 nmol/liter PGE2 equivalents for 500 #1 of CSF in a 5-ml bath (Tables 1 and 2 , and Fig. 1 ). This was considerably higher than that measured in CSF from six control patients (1.17 _+ 0.34 nmol/liter PGE2 equivalents). Among the SAH patients, the mean constrictor activity in the seven cases with severe angiographic vasospasm (67.0 _+ 41.0 nmol/liter PGE2 equivalents) was 10 times greater than that seen in the 19 patients in whom angiography did not demonstrate severe vasospasm (6.7 _+ 1.7 nmol/liter PGE2 equivalents, p < 0.01). There was no apparent graded relationship between concentration of smooth-muscle constrictor material in the CSF and the severity of angiographic vasospasm. The groups of patients with mild and moderate angiographic spasm (Table 2) were, however, very small.
Correlation with Outcome.
The greatest concentrations of vasoconstrictor material were seen in CSF samples from patients who died with evidence of delayed ischemic deficits (73.8 _+ 39.7 nmol/liter PGE2 A. H. Kaye, et al. equivalents). This was compared with values in the CSF from patients with a poor outcome (6.7 _+ 2.9 nmol/ liter PGE2 equivalents, p < 0.1), from those with a fair outcome (4.2 _+ 1.0 nmol/liter PGE2 equivalents, p < 0.2), and from those with a good outcome (6.8 + 1.8 nmol/liter PGE2 equivalents, p < 0.01). Ranking the controls as 0, good outcome as 1, fair outcome as 2, poor outcome as 3, and death as 4, there was a slight positive correlation (r = 0.74) between outcome and CSF smooth-muscle constrictor activity.
Serial lumbar CSF samples obtained from one patient (Case 2) were tested on both the rat fundus and the isolated human basilar artery. There was good agreement between the values for smooth-muscle constrictor activity estimated by these preparations (Fig. 2) . Increasing activity was associated with angiographic vasospasm, the onset of delayed ischemic deficits, and subsequent death. Tables 1 and 2 ). For a definition of outcome see text.
Discussion
Numerous in vivo and in vitro methods for the study of cerebral vasospasm have been developed. 6 While primate models might seem to be most suitable for such research, cost precludes their use in most centers. In vivo angiographic techniques using small rodents have been developed TM but, as with other live animal models, there are problems with inter-experiment variability and sample capacity. Of the in vitro models for investigating the effects of smooth-muscle constrictors on the human cerebral vasculature, the isolated human intracranial artery seems, at first, most suitable. However, a recent report has highlighted the variability of   FIG. 2 . Concentration of smooth-muscle constrictor material in the cerebrospinal fluid (CSF) of a subarachnoid hemorrhage (SAH) patient with severe angiographic spasm and delayed ischemic deficits. Four CSF samples were obtained from Case 2 (see Table 2 ) by serial lumbar puncture, and 500-ul aliquots were tested on an isolated rat stomach fundus preparation (closed circles) and an isolated human basilar artery (closed squares). Contractile responses were expressed in equivalent concentrations of PGE2 (nmol/liter). Angiography performed 7 days after SAH demonstrated severe vasospasm. Ischemic deficits were observed on Day 8, and the patient's condition deteriorated until death on Day 18. There was good agreement between the contractile responses of the rat ftmdus to CSF samples and the responses of human basilar artery to the same CSF. such preparations, 13 making accurate, comparable bioassays of a large number of CSF samples difficult. Accordingly, the isolated rat stomach fundus 4~ was chosen for estimation of smooth-muscle constrictor activity. Boullin, et al.? ~ have shown that the responses of this preparation to a wide range of physiological fluids (including post-SAH CSF) are very similar to the responses obtained from isolated human cerebral vessels. Furthermore, good correlations have been demonstrated between smooth-muscle constrictor activity of serial CSF samples (obtained after SAH), when assayed on both isolated rat fundus and isolated human basilar artery preparations? 8 Similar results were seen with serial samples of CSF from Case 2 ( Table 2 and Fig. 2) . Recent research has also shown similar profiles of serotoninergic receptor response to post-SAH CSF, for both preparations. 36 Accordingly, the rat stomach preparation was chosen for maximum reproducibility of bioassay, using serotonin and PGE2 as external standards of smooth-muscle constrictor compounds.
No significant differences were seen between the concentration of smooth-muscle constrictor material in lumbar CSF and that in ventricular CSF. Although the number of patients studied was small, this suggests that significant gradients of vasoactive materials may not occur in the CSF after SAH in the way that tryptophan metabolite gradients 32 occur in patients without evidence of subarachnoid blood. A similar lack of a ventricular/lumbar gradient has recently been demonstrated for concentrations of serotonin in CSF from patients after aneurysm rupture, 4~ Fisher, et al., j6 in a study of 50 SAH cases, reported delayed ischemic deficits in 25 patients, all of whom showed severe angiographic spasm. However, severe vasospasm was reported in six patients without concomitant ischemic deficits. Similar results were seen in the present study. Three of our seven patients who died (Cases 1, 2, and 3, Table 2 ) showed severe angiographic vasospasm and ischemic deficits (angiography was not performed in Cases 4 to 7). However, three patients with a good outcome (Cases 14, 15, and 16, Table 2 ) showed severe arterial narrowing at angiography, but no associated neurological deficits.
Angiography was clinically justified in only 26 out of 32 cases. There were insufficient numbers of patients with either mild or moderate vasospasm to demonstrate a graded relationship between angiographic vasospasm and smooth-muscle constrictor activity in CSF. However, the mean concentration of smooth-muscle constrictor material was significantly greater in seven cases with severe angiographic arterial narrowing compared with 19 patients without angiographic spasm. The value of these data is strengthened by the fact that the mean time of CSF collection (11.1 + 1.5 days) was not significantly different from the mean time of angiography (10.9 + 1.1 days)for all patients.
Analysis of the data in Table 2 and Fig. 1 shows that the concentrations of smooth-muscle constrictor sub-stances in the CSF of patients who subsequently died was significantly elevated in comparison with all other SAH patients (p < 0.01, two-tailed unpaired t-test), despite the small size of the group and the wide range of the values measured. Values were also elevated in comparison with those obtained in patients with a "poor" outcome and residual neurological deficits, but less significantly so (p < 0.1). In one patient with severe angiographic vasospasm and delayed ischemic deficits (Case 2, Table 2 and Fig. 2) , CSF smooth-muscle constrictor activity increased from 191.2 nmol/liter PGE2 equivalents on Day 7 to 302.4 nmol/liter PGE2 equivalents on Day 14. Focal ischemic deficits were observed on Day 8, and slowly increased in severity until death occurred 10 days later. This suggests a link between spasm, pharmacological activity, and outcome.
There were some anomalous results in terms of the concentration of smooth-muscle constrictor activity and both outcome (Cases 7 and 21) and angiographic vasospasm (Cases 16 and 21); however, there was a slight correlation (r = 0.74) between pharmacological activity of CSF and ranked outcome, despite the wide range of values in the group of patients who subsequently died. The lack of an obvious graded relationship between smooth-muscle constrictor substances in the CSF and clinical outcome is not surprising. Many factors may contribute to the clinical state, including high intracranial pressure, intracerebral clots, and focal exacerbations of cerebral vasospasm which may not be visualized by cerebral angiography, even if performed at the appropriate time. However, the slight correlation detected suggests that a vasoconstrictor stress exerted by unidentified smooth-muscle constrictor substances in the CSF may affect recovery from ruptured aneurysms, possibly by acting on small vessels which cannot be visualized angiographically.
Cerebral arteries, both in vivo and in vitro, have been shown to be responsive to a very large range of physiologically occurring substances. These include angiotensin 1I, 3.20 serotonin, 9"~4"36 potassium, 13 Of all these substances, only vasopressinfl 6 hemoglobin, 39 and serotonin 36' 4~ have been detected in increased concentrations in CSF obtained from patients after SAH. None of these studies was able to demonstrate an unequivocal relationship between the presence of a specific vasoconstrictor substance in the CSF, arterial narrowing as detected by angiography, and clinical cerebral vasospasm. The data presented in this paper suggest that the concentrations of smooth-muscle constrictor substances in the CSF are elevated in patients showing arterial narrowing and clinical spasm after SAH. Unfortunately, insufficient material was collected from the small group of patients (Cases 1, 2, and 3) who demonstrated angiographic and clinical spasm resulting in death, to attempt a separation and characterization of pharmacologically active substances. However, a previous study at this center 8 demonstrated that contractions of smooth-muscle preparations elicited by CSF obtained from SAH patients were not mediated by receptors for serotonin, histamine, norepinephrine (a and fl), acetylcholine, or angiotensin.
The origin of the smooth-muscle constrictor substances appearing in CSF remains obscure. It is possible that they are released by damaged brain tissue, or they may be derived from blood. 33 The relationship between the degree of CSF/blood admixture and concentration of smooth-muscle constrictor material in the CSF was not investigated in the present study, due to the difficulty of obtaining reliable hematocrit measurements in the presence of cell debris and clot material.
Previous investigations of the clinical pharmacology of cerebral vasospasm at this center 5'8"j~ have focused on the relationship between smooth-muscle constrictor substances in CSF collected postoperatively, and subsequent angiographic spasm. One study 2~ was extended to the preoperative period, and CSF activity generally declined throughout the period of hospitalization (up to 43 days after SAH), but increased in cases showing sudden clinical deterioration with development of ischemic deficits. A similar result was seen with Case 2 (Table 2 and Fig. 2) .
The presence of high concentrations of CSF smoothmuscle constrictor activity in patients who subsequently died of their disease, and of a positive correlation (r = 0.74) between the pharmacological activity of the CSF and ranked outcome, suggests that bioassay of preoperatively collected CSF might be used to detect patients at greatest risk. There could also be a case for serial lumbar punctures in selected patients to determine if CSF activity is increasing or declining.
However, the occurrence of highly active CSF in the absence of clinical deficits or angiographic evidence of spasm in an isolated instance (Case 21), and low concentrations of constrictor material in the CSF of two patients who died (Cases 6 and 7), implies that the relationship between vasospasm and pharmacological activity is not straightforward. Nevertheless, the data indicate that CSF sampling for assessment of smoothmuscle constrictor activity might be clinically useful in selected patients after aneurysm rupture.
